comparemela.com

Latest Breaking News On - Nasdaq npce - Page 2 : comparemela.com

NeuroPace, Inc (NASDAQ:NPCE) Receives Average Recommendation of Moderate Buy from Brokerages

Shares of NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the five research firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month target […]

NeuroPace, Inc (NASDAQ:NPCE) Insider Martha Morrell Sells 827 Shares

NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) insider Martha Morrell sold 827 shares of the firm’s stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $15.03, for a total transaction of $12,429.81. Following the sale, the insider now owns 109,200 shares of the company’s stock, valued at […]

NeuroPace (NASDAQ:NPCE) Price Target Increased to $9 00 by Analysts at JPMorgan Chase & Co

NeuroPace (NASDAQ:NPCE – Free Report) had its price target lifted by JPMorgan Chase & Co. from $6.00 to $9.00 in a research note released on Tuesday, Benzinga reports. They currently have an overweight rating on the stock. NPCE has been the topic of several other research reports. Morgan Stanley raised shares of NeuroPace from an […]

NeuroPace to Report Third Quarter 2023 Financial Results on

MOUNTAIN VIEW, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on.

Wells Fargo & Company Boosts NeuroPace (NASDAQ:NPCE) Price Target to $9 00

NeuroPace (NASDAQ:NPCE – Get Free Report) had its target price increased by analysts at Wells Fargo & Company from $6.00 to $9.00 in a report issued on Wednesday, FlyOnTheWall reports. Wells Fargo & Company‘s price target would suggest a potential upside of 7.02% from the company’s previous close. Separately, Morgan Stanley upgraded NeuroPace from an […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.